• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » GSK opens new global vaccines R&D center in Rockville, Maryland

GSK opens new global vaccines R&D center in Rockville, Maryland

December 13, 2016
CenterWatch Staff

GlaxoSmithKline will inaugurate its newest global vaccines research and development (R&D) center in Rockville, Maryland, further strengthening and expanding its vaccines presence in the USA. Up to 200 new jobs will be created at the Rockville facility, with GSK investing over $50 million in the next two years to continue to develop the site with latest state-of-the-art scientific research technology and equipment.

The facility will officially be opened by Sir Andrew Witty, CEO of GSK; Luc Debruyne, president of Global Vaccines, GSK; and Boyd Rutherford, Lieutenant Governor of Maryland at an event with 150 guests, including state and local officials, senior representatives of health institutions, academic partners and GSK employees.

Debruyne said, “We are delighted to be opening our new facility in Rockville, GSK’s first fully dedicated vaccines R&D center located in the U.S. Our investment here signifies our commitment to discovering and developing new vaccines across a range of pressing public health priorities, including those important here in the U.S. It places GSK at the heart of a dynamic and cutting edge bioscience hub in Washington, D.C. We look forward to fruitful partnerships and collaborations in this community to advance the science of vaccines, and help improve health of millions of people around the world.”

Under the leadership of Dr. Ripley Ballou, VP and head of GSK’s global vaccines R&D center in Rockville, the facility will house a total of 12 critical vaccine development programs. This includes projects supporting its candidate shingles vaccine, which was filed for approval with the FDA in October 2016. In addition, R&D programs for respiratory syncytial virus (RSV), a major cause of respiratory infections in young children and the elderly, Group B Streptococcus (GBS), a bacterial infection affecting newborns and dengue fever will be based at the site. Rockville becomes one of three global vaccines R&D centers for GSK, complementing the company’s existing global R&D centers in Rixensart, Belgium and in Siena, Italy.

Rockville is also the location of GSK’s proposed biopreparedness organization (BPO), a dedicated, permanent organization using a "no profit/no loss" model that will design and develop new vaccines against emerging viruses, bacteria and other pathogens that potentially pose a threat to global public health. GSK hopes the BPO will make an important contribution to improving global health preparedness.

The Rockville site, which was acquired by GSK in 2012 from Human Genome Sciences, offers proximity to current research partners, including the NIH and PATH, as well as important public health stakeholders. Since 2015, GSK has been preparing the site, transferring key staff and projects, installing equipment and modernizing the site ahead of its official opening.

GSK’s vaccines business is one of the largest in the world. It has the broadest portfolio of the industry, making available 39 pediatric, adolescent, adult and traveler vaccines that protect against 21 different diseases including hepatitis, meningitis, influenza, pneumococcal disease and rotavirus. GSK has 15 candidate vaccines in development against diseases including shingles, RSV, Group B Strep and COPD exacerbations. Over 1.9 million vaccines are delivered by GSK every day to people across more than 150 countries worldwide.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing